Efficacy and Safety of a Low-Level Light Therapy for Androgenetic Alopecia: A 24-Week, Randomized, Double-Blind, Self-Comparison, Sham Device-Controlled Trial : Dermatologic Surgery

Secondary Logo

Journal Logo

Original Article

Efficacy and Safety of a Low-Level Light Therapy for Androgenetic Alopecia: A 24-Week, Randomized, Double-Blind, Self-Comparison, Sham Device-Controlled Trial

Mai-Yi Fan, Sabrina PhD*; Cheng, Yu-Pin MD; Lee, Ming-Yung PhD; Lin, Sung-Jan MD, PhD*,§,‖,¶; Chiu, Hsien-Yi MD, PhD*,§,**

Author Information
Dermatologic Surgery 44(11):p 1411-1420, November 2018. | DOI: 10.1097/DSS.0000000000001577

Abstract

BACKGROUND 

Previous studies have reported the benefits of low-level/light laser therapy (LLLT) for the promotion of hair regrowth. However, the effectiveness of LLLT for the treatment of androgenetic alopecia (AGA) is still a topic of debate.

OBJECTIVE 

To investigate the efficacy and safety of LLLT on hair regrowth in patients with AGA.

METHODS 

This 24-week, randomized, double-blind, self-comparison, sham device-controlled trial enrolled 100 patients with AGA. All participants were randomly assigned to receive the investigational LLLT on one side of the head and sham light treatment on the contralateral side, 3 times weekly for 30 minutes each, over a 24-week period. Global scalp photography, phototrichogram assessment, the investigator's global assessment (IGA) of hair regrowth, and the subject's assessment of the treatment satisfaction were used for evaluation.

RESULTS 

After 24 weeks of treatment, the LLLT-treated scalp exhibited significantly greater hair coverage than the sham light-treated side (14.2% vs. 11.8%, p < .001). A significantly greater improvement from baseline in hair thickness, hair count, hair coverage, and IGA were also observed in the LLLT-treated side than in the sham light-treated side at the 12- and 24-week visits. No serious adverse events were observed.

CONCLUSION 

The use of LLLT might be an effective, safe, well-tolerated treatment for AGA.

© 2018 by the American Society for Dermatologic Surgery, Inc. Published by Wolters Kluwer Health, Inc. All rights reserved.

You can read the full text of this article if you:

Access through Ovid